RNTX – rein therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein Therapeutics (NASDAQ:RNTX) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at Citigroup Inc. to a "hold" rating.
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
Form 8-K Rein Therapeutics, Inc. For: Feb 16
Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP
Form 8-K Rein Therapeutics, Inc. For: Jan 15
Form 8-K Rein Therapeutics, Inc. For: Dec 11
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.